Layoff
Jan 2024A former senior scientist said her role at Kernal Biologics was affected by company-wide layoffs in 2024.
SourceKernal is creating mRNA 2.0 therapies that work in specific cells
Company research
Public company, workplace, funding, and market signals
Overview
Cambridge-based venture-backed biotech developing AI-designed, cell-selective mRNA-LNP therapeutics ('mRNA 2.0') for in vivo cell therapy, including CAR-T programming, and licensing the platform for non-oncology uses.
Primary product
mRNA 2.0 platform and KR-402 in vivo CAR-T program
Founded
2016
Headquarters
Cambridge, Massachusetts, United States
Team size
11-50 employees
Industry
Biotechnology Research
Sub-industry
mRNA therapeutics / in vivo cell therapy
Offices
Cambridge, Massachusetts, United States
Open Positions
4 jobs at Kernal Biologics
Vice President, Chemistry, Manufacturing & Controls (CMC) – mRNA-tLNP Therapeutics
On-siteR&DBoston, MA1w ago
On-site